Deal Tracker · Countries

South Korea pharma deals

14 pharma deals involving South Korea — companies based there or deals covering the market — tracked by EPT: licensing, distribution & localization. Most active: Arcera Life Sciences, Celltrion, Korea United Pharm & Samsung Bioepis. Latest: Celltrion → Brazilian federal government (Supply / Manufacturing, 17 Nov 2026).

14
deals tracked
12
announced in 2026
$733.9m
disclosed value (6 deals)
43%
licensing, the top deal type
  • EPT has tracked 14 South Korea pharma deals (2025–2026), 12 of them announced in 2026.
  • The most common structures are licensing (43%), distribution (29%) & localization (14%).
  • Values were disclosed for 6 of 14 deals, totalling $733.9m; the largest is AriBio → Arcera Life Sciences ($600m, 10 Jun 2025).
  • The most active companies: Arcera Life Sciences (2), Celltrion (2), Korea United Pharm (2) & Samsung Bioepis (2).

Most active companies

Arcera Life Sciences (2) · Celltrion (2) · Korea United Pharm (2) · Samsung Bioepis (2)

Countries involved

Brazil (3) · UAE (3) · Philippines (2) · Saudi Arabia (2) · Bahrain (1) · Egypt (1)

Largest disclosed deals

Questions

How many South Korea pharma deals has EPT tracked?
14 as of 17 Nov 2026, covering 2025–2026; 12 were announced in 2026. The most recent is Celltrion → Brazilian federal government (Supply / Manufacturing, 17 Nov 2026).
What types of South Korea pharma deals are most common?
Licensing: 6 (43%); Distribution: 4 (29%); Technology transfer / Localization: 2 (14%); Partnership / Collaboration: 1 (7%).
Which companies are most active in South Korea pharma deals?
Arcera Life Sciences (2 deals), Celltrion (2 deals), Korea United Pharm (2 deals), Samsung Bioepis (2 deals).
What is the largest disclosed South Korea pharma deal?
AriBio → Arcera Life Sciences: $600m (Licensing, 10 Jun 2025); Daewoong Pharmaceutical → Arcera Life Sciences: $94m (Licensing, 29 Jun 2026); Hanmi Pharmaceutical → Organon: $34m (Distribution, 21 May 2026). Values are as announced by the parties.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)